Headcount: 15,400
Year Established: 1988
Revenues: $14,343 (1%)
Net Income: $4,505 (2%)
R&D expenses: $5,850 (14%)

Bringing in $14.3 billion for the year, Regeneron’s revenues increased 1% thanks to its blockbuster medicines Dupixent, Eylea HD Injection 8 mg and Eylea Injection, the sales of which have historically represented a large portion of its revenues. The company’s focus remained on prioritizing internal investments and complementary business development opportunities. As such Regeneron invested $5.9 billion or approximately 41% of 2025 revenues in R&D.

Supporting growth, Regneron’s flagship Dupixent received several label expansions including the treatment of adults with bullous pemphigoid and adult and pediatric patients with allergic fungal rhinosinusitis who have a history of sino-nasal surgery. Most recently, Dupixent won a pediatric indication for chronic spontaneous urticaria.

In November, the FDA approved Eylea HD Injection 8 mg for patients with macular edema following retinal vein occlusion with up to every 8-week dosing, and a once monthly dosing option for some patients. The FDA also approved the extension of dosing intervals for Eylea HD up to every 20 weeks for patients with wAMD and diabetic macular edema. Lastly, PD-1 inhibitor Libtayo was approved as an adjuvant treatment for cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation.

Regeneron entered several new partnerships. A global collaboration with Tessera Therapeutics aims to advance TSRA-196, its investigational in-vivo Gene Writing program for the treatment of alpha-1 antitrypsin deficiency.

Regeneron also joined forces with Telix Pharma to develop and commercialize next-gen radiopharmaceutical therapies for multiple solid tumor targets from Regeneron’s portfolio of antibodies. Most recently, a research pact with Parabilis Medicines aims to develop multiple therapeutic candidates based on Parabilis’ Helicon peptide platform, with a focus on Antibody-Helicon Conjugates, a novel class of therapeutics designed to target challenging and historically “undruggable” targets.

The company also announced an agreement with the U.S. government to help lower prices of several of its current and future medicines and offer an important new medicine for free in the U.S. As part of the agreement, Regeneron will lower Medicaid prices based on those in other developed countries and will align U.S. prices of future medicines with prices set in that defined group of other countries. Regeneron will also utilize the TrumpRx.gov platform to allow eligible patients to directly purchase Praluent, Regeneron’s PCSK9 inhibitor medicine, at the most-favored nation price.

Headcount: 1,950
Bio/Pharma Revenues: $858 (1807%)
Total Revenues: $1,378 (209%)
Net Income: $750 (n/a)
R&D Budget: $626 (18%)

Top Selling Drugs

Account for 98% of total biopharma sales, up from 44% in 2011